Nanoscope Therapeutics recently reported breakthrough data from their Phase 2 RESTORE clinical trial of MCO-010 in advanced Retinitis Pigmentosa (RP) patients. In this trial, 16 of 18 treated RP patients experienced a clinically meaningful improvement in navigational vision or small object recognition. Nanoscope also recently revealed key 6-mo data from STARLIGHT, a Phase 2 trial of MCO-010 in Stargardt Macular Degeneration (SD) patients. Several of these patients also experienced significant improvements including the ability to read several additional lines of letters on an eye chart, utilize mass transportation, participate in recreational activities, and go back to work independently.
Due to the gene-agnostic nature of MCO therapy in multiple IRDs involving outer retinal degeneration, Nanoscope believes that choroideremia patients might benefit from MCO-010 treatment as well. This presentation will review Nanoscope's MCO-010 trials to date and discuss their future plans for development.